About DermBiont
DermBiont is a company based in Melrose (United States) founded in 2015 by Nichola Eliovits.. DermBiont has raised $78.91 million across 8 funding rounds from investors including Illumina, Viking Global Investors and Civilization Ventures. The company has 14 employees as of December 31, 2024. DermBiont has completed 1 acquisition, including SeylanMED. DermBiont offers products and services including Pipeline Platform and Small Molecules. DermBiont operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Melrose, United States
- Employees 14 as on 31 Dec, 2024
- Founders Nichola Eliovits
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dermbiont, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DermBiont
DermBiont offers a comprehensive portfolio of products and services, including Pipeline Platform and Small Molecules. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for advancing topical therapeutics in skin diseases
Compounds targeting root causes of dermatology conditions
Unlock access to complete
Unlock access to complete
Funding Insights of DermBiont
DermBiont has successfully raised a total of $78.91M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $32.7 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $32.7M
- First Round First Round
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series B - DermBiont | Valuation | Double Point Ventures | |
| Mar, 2023 | Amount | Debt – Conventional - DermBiont | Valuation |
investors |
|
| Sep, 2022 | Amount | Debt – Conventional - DermBiont | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in DermBiont
DermBiont has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Illumina, Viking Global Investors and Civilization Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital is provided to health tech and biology innovations.
|
Founded Year | Domain | Location | |
|
Provider of a venture capital firm that invests in technology and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by DermBiont
DermBiont has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SeylanMED. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Treatments for skin disorders are developed by the company.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - DermBiont
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dermbiont Comparisons
Competitors of DermBiont
DermBiont operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dermbiont
Frequently Asked Questions about DermBiont
When was DermBiont founded?
DermBiont was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Where is DermBiont located?
DermBiont is headquartered in Melrose, United States. It is registered at Melrose, Massachusetts, United States.
Is DermBiont a funded company?
DermBiont is a funded company, having raised a total of $78.91M across 8 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $2.51M, raised on Apr 26, 2018.
How many employees does DermBiont have?
As of Dec 31, 2024, the latest employee count at DermBiont is 14.
What does DermBiont do?
DermBiont was founded in 2015 and is based in Melrose, United States. Microbial therapeutics are developed by the company to address various skin conditions within the biotechnology sector. Topical candidates include DBI-001, targeted at eczema, athletes foot, and nail fungus; DBI-002, focused on inflammatory dandruff; and SM-020, intended for benign skin tumors. Operations center on advancing these therapeutic options through research and development.
Who are the top competitors of DermBiont?
DermBiont's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does DermBiont offer?
DermBiont offers Pipeline Platform and Small Molecules.
How many acquisitions has DermBiont made?
DermBiont has made 1 acquisition, including SeylanMED.
Who are DermBiont's investors?
DermBiont has 9 investors. Key investors include Illumina, Viking Global Investors, Civilization Ventures, Olive Tree Capital, and Double Point Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.